CN113461740B - 一种铱配合物及其制备方法和应用 - Google Patents
一种铱配合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN113461740B CN113461740B CN202110899598.2A CN202110899598A CN113461740B CN 113461740 B CN113461740 B CN 113461740B CN 202110899598 A CN202110899598 A CN 202110899598A CN 113461740 B CN113461740 B CN 113461740B
- Authority
- CN
- China
- Prior art keywords
- iridium complex
- iridium
- skin cancer
- complex
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229910052741 iridium Inorganic materials 0.000 title claims abstract description 45
- GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 238000010668 complexation reaction Methods 0.000 title description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 8
- 201000000849 skin cancer Diseases 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 201000001441 melanoma Diseases 0.000 claims abstract description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 18
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- -1 hexafluorophosphate Chemical compound 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 229910021638 Iridium(III) chloride Inorganic materials 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- DANYXEHCMQHDNX-UHFFFAOYSA-K trichloroiridium Chemical compound Cl[Ir](Cl)Cl DANYXEHCMQHDNX-UHFFFAOYSA-K 0.000 claims description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Substances C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 claims description 3
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 abstract description 7
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 6
- 238000005286 illumination Methods 0.000 abstract description 6
- 238000002428 photodynamic therapy Methods 0.000 abstract description 5
- 239000003504 photosensitizing agent Substances 0.000 abstract description 5
- 201000008261 skin carcinoma Diseases 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 4
- 231100000053 low toxicity Toxicity 0.000 abstract description 4
- 150000004696 coordination complex Chemical class 0.000 abstract description 3
- 230000009036 growth inhibition Effects 0.000 abstract description 3
- 239000003560 cancer drug Substances 0.000 abstract description 2
- 230000030833 cell death Effects 0.000 abstract description 2
- 229910052751 metal Inorganic materials 0.000 abstract description 2
- 239000002184 metal Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 11
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 229960002749 aminolevulinic acid Drugs 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 150000002503 iridium Chemical class 0.000 description 5
- 238000011534 incubation Methods 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229950006238 nadide Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000001699 photocatalysis Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 206010034972 Photosensitivity reaction Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 208000007578 phototoxic dermatitis Diseases 0.000 description 2
- 231100000018 phototoxicity Toxicity 0.000 description 2
- 239000010453 quartz Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 235000005811 Viola adunca Nutrition 0.000 description 1
- 240000009038 Viola odorata Species 0.000 description 1
- 235000013487 Viola odorata Nutrition 0.000 description 1
- 235000002254 Viola papilionacea Nutrition 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0033—Iridium compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/18—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms
- B01J31/1805—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes containing nitrogen, phosphorus, arsenic or antimony as complexing atoms, e.g. in pyridine ligands, or in resonance therewith, e.g. in isocyanide ligands C=N-R or as complexed central atoms the ligands containing nitrogen
- B01J31/181—Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine
- B01J31/1815—Cyclic ligands, including e.g. non-condensed polycyclic ligands, comprising at least one complexing nitrogen atom as ring member, e.g. pyridine with more than one complexing nitrogen atom, e.g. bipyridyl, 2-aminopyridine
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
- B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
- B01J31/22—Organic complexes
- B01J31/2282—Unsaturated compounds used as ligands
- B01J31/2295—Cyclic compounds, e.g. cyclopentadienyls
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J35/00—Catalysts, in general, characterised by their form or physical properties
- B01J35/30—Catalysts, in general, characterised by their form or physical properties characterised by their physical properties
- B01J35/39—Photocatalytic properties
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/02—Compositional aspects of complexes used, e.g. polynuclearity
- B01J2531/0238—Complexes comprising multidentate ligands, i.e. more than 2 ionic or coordinative bonds from the central metal to the ligand, the latter having at least two donor atoms, e.g. N, O, S, P
- B01J2531/0241—Rigid ligands, e.g. extended sp2-carbon frameworks or geminal di- or trisubstitution
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
- B01J2531/80—Complexes comprising metals of Group VIII as the central metal
- B01J2531/82—Metals of the platinum group
- B01J2531/827—Iridium
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/18—Metal complexes
- C09K2211/185—Metal complexes of the platinum group, i.e. Os, Ir, Pt, Ru, Rh or Pd
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/30—Hydrogen technology
- Y02E60/36—Hydrogen production from non-carbon containing sources, e.g. by water electrolysis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Inorganic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
本发明涉及医药技术领域，特别涉及一种铱配合物及其制备方法和应用，该配合物应用于抗非黑色素瘤皮肤癌的光动力治疗具有较强的疗效，在光照条件下可以破坏NAD+/NADH氧化还原平衡引起细胞死亡，对人非黑色素瘤鳞状皮肤癌细胞株具有很强的生长抑制能力(IC50＝0.0003μM/0.3nM)。对于研究高效低毒的金属配合物光敏剂有重要的意义，以期为临床开发新型的金属抗非黑色素瘤皮肤癌药物奠定理论和实验基础。
Description
技术领域
本发明涉及医药技术领域，特别涉及一种铱配合物及其制备方法和应用。
背景技术
癌症已经成为威胁人类健康的重大疾病，据统计，癌症是全球第二大死因。根据统计，2020年全球新增癌症病例达到1930万，将近1000万人死于癌症，其中非黑色素瘤皮肤癌新增病例占6.2％，位居不同癌症新增病例数第四。由于皮肤癌所发生的皮肤层次和病理类型不同，目前临床上治疗皮肤癌主要是以局部外用药、激光和手术等多种治疗手段联合治疗。
光动力治疗被认为是临床具有良好靶向性的新型肿瘤治疗方法，其作用基础是利用光激发聚集在肿瘤内部的光敏剂，产生活性氧有效杀伤病变组织，同时可减少对病灶周边正常组织的杀伤，以此来获取最佳的治疗效果。目前临床上用于治疗皮肤癌较为成熟的治疗方法是利用5-氨基酮戊酸(5-ALA)进行光动力治疗，具有组织选择性好、操作简便的优点，但是临床数据显示，5-ALA在治疗皮肤癌上的临床疗效稳定性差，不同个体患者的临床疗效差异较大，研究开发新的高效低毒的光敏剂成为研究热点。
与有机化合物相比,金属配合物分子结构具有更好的可塑性，可以通过在配体上修饰引入其它分子活性基团改善其光物理和化学性质，并且金属配合物相对比较稳定，容易在体内环境产生药效，用于肿瘤光动力治疗具有极大的临床应用前景。
发明内容
针对现有技术中的上述不足，本发明提供一种铱配合物。
本发明的另一个目的在于提供上述铱配合物的制备方法。
本发明的另一个目的在于提供上述铱配合物的应用。
本发明的目的通过以下技术方案予以实现：
一种铱配合物，其机构如式(I)：
简记为Ir。
所述铱配合物的制备方法，包括以下步骤：
S1.将2,2':6',2"-三联吡啶和三氯化铱在乙二醇中反应制得铱前体；
S2.再将步骤S1得到的铱前体和2,4,6-三苯基吡啶在乙二醇中反应，反应完毕后加入六氟磷酸盐溶液，即得。
优选地，所述步骤S2中，反应温度为160～200℃，反应时间为22～26h。
优选地，所述步骤S2中，反应温度为180℃，反应时间为24h。
所述铱配合物在抗癌药物上的应用。
所述铱配合物在抗非黑色素瘤鳞状皮肤癌癌细胞的药物上的应用。
与现有技术相比，本发明具有以下技术效果：
本发明公开了一种新型的铱金属配合物及其制备方法，该配合物应用于抗非黑色素瘤皮肤癌(A431细胞)的光动力治疗具有较强的疗效，在光照条件下可以破坏NAD+/NADH氧化还原平衡引起细胞死亡，对人非黑色素瘤鳞状皮肤癌细胞株具有很强的生长抑制能力(IC50＝0.0003μM/0.3nM)。对于研究高效低毒的金属配合物光敏剂有重要的意义，以期为临床开发新型的金属抗非黑色素瘤皮肤癌药物奠定理论和实验基础。
附图说明
图1本发明实施例的铱配合物分子结构；
图2本发明实施例的铱配合物的氢谱核磁共振图谱；
图3本发明实施的铱配合物的紫外吸收和荧光发射光谱；
图4本发明实施例铱配合物对NADH的光催化氧化能力；
图5本发明实施例铱配合物对A431肿瘤细胞的暗毒性和光毒性。
具体实施方式
下面对本发明的具体实施方式作进一步说明。在此需要说明的是，对于这些实施方式的说明用于帮助理解本发明，但并不构成对本发明的限定。此外，下面所描述的本发明各个实施方式中所涉及的技术特征只要彼此之间未构成冲突就可以相互组合。
下述实验例中所使用的试验方法如无特殊说明，均为常规方法；所使用的材料、试剂等，如无特殊说明，为可从商业途径得到的试剂和材料。
实施例1
一种铱配合物其结构式如图1所示。具体如下：
160℃下，2,2':6',2"-三联吡啶(233.3mg,1mmol)和三氯化铱(328.4mg,1.1mmol)在乙二醇(8mL)中反应，搅拌反应15分钟后将反应液抽滤后得到目标铱前体，为红色固体，产率30.2％。将获得的铱前体和2,4,6-三苯基吡啶在乙二醇(10mL)中于180℃下反应，24小时后冷却至室温，加入六氟磷酸盐溶液。搅拌1小时，得到目标铱配合物(Ir)，将得到的铱配合物粗品经中性氧化铝柱色谱(溶剂：甲醇/二氯甲烷＝1/99)纯化，得到铱配合物，为红色固体，产率为36.4％。通过质谱如图2，和核磁表征，1H NMR(400MHz,DMSO-d6)δ9.07(d,J＝8.2Hz,2H),8.85(d,J＝7.5Hz,2H),8.56(s,2H),8.49(t,J＝8.2Hz,1H),8.30(d,J＝7.3Hz,2H),8.19(d,J＝7.7Hz,2H),8.06(t,J＝7.9Hz,2H),7.83(d,J＝5.9Hz,2H),7.74–7.67(m,2H),7.61(t,J＝7.3Hz,1H),7.38(t,J＝6.7Hz,2H),6.95(t,J＝7.5Hz,2H),6.71(t,J＝7.8Hz,2H),6.08(d,J＝8.4Hz,2H).ESI-MS:[M-PF6 -]+(m/z)：Calc.,731.1783；Found,731.1764。
上述方法获得的铱配合物进一步进行以下实验。
实施例2铱配合物的紫外吸收和荧光发射性质
将含铱配合物(10μM)的不同溶剂溶液的石英比色皿分别放在紫外分光光度计或荧光分光光度计中检测溶液的吸光度和在激发光为465nm的荧光发射强度，结果如图3所示，可见铱配合物的荧光发射强度与溶剂的极性相关。
实施例3铱配合物光催化氧化NADH的能力
将含铱配合物(5μM)和NADH(A339nm＝1)的PBS溶液置于石英比色皿中，放在465nm光源下辐射5min(光剂量为11.7J/cm2)，检测溶液光照前后的吸光度。结果如图4所示，铱配合物在465nm光辐射下，能将还原型辅酶Ⅰ(NADH)氧化成其氧化态(NAD+)，铱配合物对NADH有光催化氧化能力。
实施例4铱配合物对不同肿瘤细胞的暗毒性和光毒性
利用MTT比色法来分析铱配合物对不同肿瘤细胞的抗增殖效应。MTT，中文名叫噻唑蓝，是一种四唑盐，在活细胞中，线粒体内的琥珀酸脱氢酶可将MTT还原，生成一种蓝紫色产物-甲臜(可溶于DMSO)，且该产物在595nm处有吸收峰，故可用A595nm来分析细胞增殖情况。
MTT实验步骤如下：
①先复苏1管A431肿瘤细胞，用新鲜培养液(DMEM培养基+10％胎牛血清+1％盘尼西林和链霉素)培养，传代2次后使用。
②待细胞到达对数生长期时，以10000个/孔的细胞密度接种至2块96孔板中(每孔用100μL培养液培养细胞，一板为光照组，另一板为黑暗组)，送入恒温箱(310K,5％CO2)中培养。
③待其贴壁后，吸出原有培养基，每孔分别加入100μL不同浓度的铱配合物(Ir)和5-氨基酮戊酸(5-ALA)的新鲜培养液，轻轻晃匀，在恒温箱中避光孵育。
④孵育8h后，将光照组的细胞培养板置于525nm波长蓝光灯下光照10min(光剂量为29.56J/cm2)，黑暗对照组的细胞一直置于温箱中避光培养，光照结束后，放回培养箱继续避光孵育。
⑤孵育40h后，在每孔中加入10μL MTT(5mg/mL)，于37℃温箱中继续孵育4h后，吸去上清液，每孔加200μL二甲基亚砜(DMSO)，用酶标仪检测A595nm，计算细胞增殖抑制率，求出IC50值(抑制率等于50％的时候的药物浓度)。
如图5所示，MTT法检测不同浓度的铱配合物和5-ALA在黑暗与光照处理条件下对不同肿瘤细胞的杀伤作用效果不同。实验中的化合物在无光照情况下，对人鳞状皮肤癌细胞株A431没有毒性，但是在光照条件下铱配合物对A431肿瘤细胞株具有很强的生长抑制能力(IC50＝0.0003μM/0.3nM)，而对照的化合物如5-ALA(IC50＝135.58μM)在相同实验条件下对肿瘤细胞的生长抑制能力远远不如本发明的铱配合物，证明本专利的铱配合物具有开发成为高效低毒的光敏剂的巨大潜力。
以上所述仅为本发明专利的较佳实施例而已，并不用以限制本发明专利，凡在本发明专利的精神和原则之内所作的任何修改、等同替换和改进等，均应包含在本发明专利的保护范围之内。
Claims (5)
1.一种铱配合物，其特征在于，其结构式如式(I)：
2.权利要求1所述铱配合物的制备方法，其特征在于，包括以下步骤：
S1.将2,2':6',2"-三联吡啶和三氯化铱在乙二醇中反应制得铱前体；
S2.再将步骤S1得到的铱前体和2,4,6-三苯基吡啶在乙二醇中反应，反应完毕后加入六氟磷酸盐溶液，即得；
所述铱前体的结构式为：
3.根据权利要求2所述铱配合物的制备方法，其特征在于，所述步骤S2中，反应温度为160～200℃，反应时间为22～26h。
4.根据权利要求3所述铱配合物的制备方法，其特征在于，所述步骤S2中，反应时间为24h；反应温度为180℃。
5.权利要求1所述铱配合物在制备抗非黑色素瘤鳞状皮肤癌的药物中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110899598.2A CN113461740B (zh) | 2021-08-06 | 2021-08-06 | 一种铱配合物及其制备方法和应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110899598.2A CN113461740B (zh) | 2021-08-06 | 2021-08-06 | 一种铱配合物及其制备方法和应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113461740A CN113461740A (zh) | 2021-10-01 |
| CN113461740B true CN113461740B (zh) | 2023-06-30 |
Family
ID=77866258
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110899598.2A Active CN113461740B (zh) | 2021-08-06 | 2021-08-06 | 一种铱配合物及其制备方法和应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113461740B (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111662333A (zh) * | 2019-03-07 | 2020-09-15 | 天津理工大学 | 一类双三联吡啶铱(ⅲ)配合物及其合成方法 |
| CN115925617A (zh) * | 2022-08-25 | 2023-04-07 | 中山大学·深圳 | 一种氘代钌配合物及其制备方法和在光催化抗肿瘤中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180135522A (ko) * | 2017-06-12 | 2018-12-21 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 장치 |
| CN110615815A (zh) * | 2019-07-12 | 2019-12-27 | 中山大学 | 一种新型广谱肿瘤光治疗活性的金属配合物光敏剂及其制备方法和应用 |
| CN113150034A (zh) * | 2021-05-06 | 2021-07-23 | 中山大学 | 一种双核金属铱配合物及其制备方法和应用 |
-
2021
- 2021-08-06 CN CN202110899598.2A patent/CN113461740B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180135522A (ko) * | 2017-06-12 | 2018-12-21 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 장치 |
| CN110615815A (zh) * | 2019-07-12 | 2019-12-27 | 中山大学 | 一种新型广谱肿瘤光治疗活性的金属配合物光敏剂及其制备方法和应用 |
| CN113150034A (zh) * | 2021-05-06 | 2021-07-23 | 中山大学 | 一种双核金属铱配合物及其制备方法和应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113461740A (zh) | 2021-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113461740B (zh) | 一种铱配合物及其制备方法和应用 | |
| CN111875604A (zh) | 一类线粒体靶向和光动力治疗的β-咔啉鎓盐的荧光化合物及其制备方法和应用 | |
| CN110372754B (zh) | 一种新型金属铱配合物及其制备方法和应用 | |
| AU2018282411A1 (en) | Chlorin derivative useful in photodynamic therapy and diagnosis | |
| CN113512070B (zh) | 一种具有近红外荧光的钌配合物及其制备方法和应用 | |
| CN112358519B (zh) | 一种葡萄糖修饰强光吸收铱光敏剂及其制备方法和应用 | |
| CN114045045A (zh) | 一类单光子上转换五甲川菁类光敏染料、其制备方法和应用 | |
| CN110423260B (zh) | 一种葡萄糖修饰的环金属化铱光敏剂及其制备方法和应用 | |
| WO2009040411A1 (en) | Photodynamic therapy and diagnosis using a chlorin e4 zinc complex | |
| CN112480176B (zh) | 一种新型靶向溶酶体钌光催化剂及其制备方法和应用 | |
| CN113603726B (zh) | 一种双核铱配合物及其制备方法和应用 | |
| CN113603698B (zh) | 具有i型光敏反应和光热协同效应的酞菁-奋乃静偶联物与在制药领域的应用 | |
| CN111393482B (zh) | 一种铂-铱异核金属配合物及其制备方法和应用 | |
| CN113603740B (zh) | 一种采用橙色光激发铱配合物及其制备方法和应用 | |
| RU2372099C1 (ru) | Иттербиевые комплексы тетрапиразолилпорфиринов как флуоресцентные метки для диагностики злокачественных новообразований | |
| CN113024603B (zh) | 一种白光引发自偶联的有机小分子光敏剂及其制备方法和应用 | |
| CN116425732B (zh) | 一种具有线粒体靶向功能的光可控释放no并开启光动力效果的光敏剂及其制备方法和应用 | |
| CN114957105B (zh) | 一种双羰基配体及其制备方法和应用 | |
| CN113583057B (zh) | 一种高效金属铱配合物及其制备方法和应用 | |
| CN112294956B (zh) | 一种金属铱光敏剂及其制备方法和应用 | |
| CN117903037A (zh) | 一种靶向线粒体的聚集诱导发光光敏剂及其制备方法与应用 | |
| CN117658786A (zh) | 竹红菌素衍生物及其制备方法和应用 | |
| CN117362352A (zh) | 一种双核钌光催化剂及其制备方法与在光催化抗三阴性乳腺癌中的应用 | |
| CN106957319B (zh) | 二氢卟啉衍生物和制备方法及应用 | |
| CN117701025A (zh) | 尼罗蓝-parp抑制剂染料及其合成方法与应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |